Naming human medicines
- Medicines and Healthcare products Regulatory Agency
- Part of:
- How to reclassify your medicine and Patient safety
- First published:
- 23 December 2009
Guidance on naming human medicines, including Braille requirements for the name on the product label.
PDF, 235KB, 20 pages
This file may not be suitable for users of assistive technology. Request an accessible format.
If you use assistive technology (such as a screen reader) and need a version of this document in a more accessible format, please email email@example.com. Please tell us what format you need. It will help us if you say what assistive technology you use.
This Medicines and Healthcare products Regulatory Agency (MHRA) guidance for the pharmaceutical industry selecting or constructing a product name covers:
- the criteria used to assess the suitability of invented names
- additional criteria used to assess the suitability of invented names for non-prescription medicines
- criteria used in assessing the suitability of qualifiers/abbreviations
- criteria used in assessing the acceptability of umbrella segments of product names
- criteria for the generic naming of medicines, international non-proprietary names or common name
Published: 23 December 2009